ClinicalTrials.gg
CompletedNCT05687903Updated Jan 9, 2025Results posted

A Study of TAK-861 in Participants With Narcolepsy Type 1

A Phase 2 interventional study of TAK-861 and Placebo in Narcolepsy Type 1, sponsored by Takeda. Completed at 57 sites in 12 countries. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-01-09.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
16 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Narcolepsy by Takeda — 4 open to participants now, 6 under way, 2 of them phase 3. Narcolepsy · Takeda.

Enrollment
3rd of 12
112 · median 95
Started
2023
with 2 others
Phase 2
6 of 16
2 open now
Registered
7th of 16
by date

Among the 16 studies in Narcolepsy by Takeda, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2023, is one of 6 in phase 2, and was the 7th registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

4 of the 16 studies in Narcolepsy by Takeda are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 16 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Narcolepsy by Takeda, or all of them as a file.
02

Study summary

The main aim of this study is to see how TAK-861 works on symptoms of narcolepsy, including excessive daytime sleepiness and cataplexy. Approximately 100 participants will take part in the study across North America, Europe and Asia Pacific.

The treatment (TAK-861 or placebo) will be administered for 8 or 12 weeks. After this treatment period the participant will have the option to participate in a separate, long- term extension study during which all participants will be treated with TAK-861.

Read the detailed description

The drug being tested in this study is called TAK-861. This study will look at the effect of TAK-861 on improvement in narcolepsy symptoms, including excessive daytime sleepiness (EDS) and number of cataplexy episodes.

The study will enroll approximately 100 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the five treatment groups which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

  • TAK-861 Dose 1
  • TAK-861 Dose 2
  • TAK-861 Dose 3
  • TAK-861 Dose 4
  • Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has no active ingredient

This multi-center trial will be conducted worldwide. The overall time to participate in this study is up to 23 weeks. Participants will make multiple visits to the clinic during the treatment period and then will either enroll in a long-term extension study in which all participants will receive TAK-861 or have 2 final visits 7 and 28 days after last dose of study drug for follow-up assessments.

03

Conditions studied

  • Narcolepsy Type 1

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
16 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant is aged 18 to 70 years, inclusive, at the time of signing the form (ICF).

    Note: In Japan, participants aged 16 to 70 years, inclusive, may be included.

  2. The participant has (BMI) within the range 18 to 40 kilogram per square meter [kg/m\^2] (inclusive).
  3. The participant has an International Classification of Sleep Disorders, 3rd Edition (ICSD-3) diagnosis of narcolepsy type 1 (NT1) by polysomnography (PSG)/Multiple Sleep Latency Test (MSLT), performed within the past 10 years.
  4. The participant is positive for the human leukocyte antigen (HLA) genotype HLA-DQB1*06:02 or results from cerebrospinal fluid (CSF) testing indicate the participant's CSF orexin (OX)/hypocretin-1 concentration is \<110 picograms per milliliter ([pg/mL] (or less than one-third of the mean values obtained in normal participants within the same standardized assay).

Exclusion criteria

Exclusion Criteria:

  1. The participant has a current medical disorder, other than narcolepsy with cataplexy, associated with EDS.
  2. The participant has medically significant hepatic or thyroid disease.
  3. The participant has a history of cancer in the past 5 years (does not apply to participants with carcinoma in situ that has been resolved without further treatment or basal cell cancer).
  4. The participant has coronary artery disease, a history of myocardial infarction, clinically significant angina, clinically significant cardiac rhythm abnormality, or heart failure.
  5. The participant has a clinically significant history of head injury or head trauma.
  6. The participant has history of epilepsy, seizure, or convulsion, or has a family history of inherited disorders associated with seizure (except for a single febrile seizure in childhood).
  7. The participant has one or more of the following psychiatric disorders:

    1. Any current unstable psychiatric disorder.
    2. Current or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including schizoaffective disorder, major depression with psychotic features, bipolar depression with psychotic features, obsessive compulsive disorder, intellectual disability, organic mental disorders, or mental disorders due to a general medical condition as defined in the , 5th Edition (DSM-5).
    3. Current diagnosis or history of substance use disorder as defined in the DSM-5.
    4. Current active major depressive episode (MDE) or who have had an active MDE in the past 6 months.
  8. The participant has a history of cerebral ischemia, (\<5 years ago), intracranial aneurysm, or arteriovenous malformation.
  9. The participant has a positive test result for surface antigen, virus antibody, or (HIV) antibody/antigen.
  10. The participant's renal (Cockcroft-Gault Equation) is ≤50 mL/minute.
  11. The participant has (ALT) or aspartate aminotransferase (AST) values >1.5 times the (ULN).
  12. The participant is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property, or the participant has attempted suicide within the past year.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
112 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo tablets matching TAK-861, orally, twice daily (BID), from Days 1 to 56.

    Drug: Placebo

  • Experimental
    TAK-861 0.5 mg BID

    Participants received TAK-861 0.5 milligrams (mg), orally, BID, from Days 1 to 56.

    Drug: TAK-861

  • Experimental
    TAK-861 2 mg BID

    Participants received TAK-861 2 mg, orally, BID, from Days 1 to 56.

    Drug: TAK-861

  • Experimental
    TAK-861 2 mg and 5 mg

    Participants received TAK-861 2 mg followed by 5 mg dose, orally, BID, from Days 1 to 56.

    Drug: TAK-861

  • Experimental
    TAK-861 7 mg QD

    Participants received TAK-861 7 mg, orally, once daily (QD), from Day 1 to 56. Placebo was given as the second dose.

    Drug: TAK-861 · Drug: Placebo

Interventions

  • TAK-861 oral tablets

  • DrugPlacebo

    Placebo oral tablets matching TAK-861

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Average Sleep Latency as Determined From the MWT at Week 8

    The MWT is a validated, objective measure that evaluates a participant's ability to remain awake under soporific conditions for a defined period. During each MWT session (1 session = 40 minutes), participants were instructed to sit quietly and remain awake for as long as possible. Sleep latency in each session was recorded on EEG. If no sleep was observed according to these rules, then the latency was defined as 40 minutes. The linear mixed effects model for repeated measures (MMRM) was used for analysis.

    Time frame: Baseline, Week 8

Secondary outcomes

  1. Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score at Week 8

    The ESS is a subjective, self-administered, validated scale (scored 0 to 3) to respond to each of the 8 questions of daily life that asks participants how likely they are to fall asleep in those situations. The scores are summed to give an overall score of 0 to 24. Higher scores indicate stronger subjective daytime sleepiness, and scores below 10 are considered to be within the normal range. The MMRM was used for analysis.

    Time frame: Baseline, Week 8

  2. Weekly Cataplexy Rate (WCR) at Week 8

    Participants completed a daily patient-reported sleep diary to record self-reported narcolepsy symptoms. Participants recorded episodes of cataplexy attacks in the diary. The total number of events averaged for a week were reported. WCR = (total number of cataplexy attacks over a number of non-missing diary days for a given duration/number of non-missing diary days in that duration)\*7. The generalized estimating equations (GEE) model was used for analysis.

    Time frame: Week 8

  3. Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE)

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not the occurrence was considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an AE with an onset that occurred after receiving study drug.

    Time frame: From first dose of the study drug up to end of the study (up to 3 months)

07

Results

Posted Jan 9, 2025

Participant flow

Participants took part in the study at 33 investigative sites globally from 09 January 2023 to 14 December 2023.

Participant flow — Overall Study
MilestonePlaceboTAK-861 0.5 mg BIDTAK-861 2 mg BIDTAK-861 2 mg and 5 mgTAK-861 7 mg QD
Started2223212323
Completed2122212223
Not completed11010
Withdrew: Protocol deviation11010

Outcome measures

PrimaryChange From Baseline in the Average Sleep Latency as Determined From the MWT at Week 8

The MWT is a validated, objective measure that evaluates a participant's ability to remain awake under soporific conditions for a defined period. During each MWT session (1 session = 40 minutes), participants were instructed to sit quietly and remain awake for as long as possible. Sleep latency in each session was recorded on EEG. If no sleep was observed according to these rules, then the latency was defined as 40 minutes. The linear mixed effects model for repeated measures (MMRM) was used for analysis.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · minutes
Change From Baseline in the Average Sleep Latency as Determined From the MWT at Week 8
minutesPlaceboTAK-861 0.5 mg BIDTAK-861 2 mg BIDTAK-861 2 mg and 5 mgTAK-861 7 mg QD
Change From Baseline in the Average Sleep Latency as Determined From the MWT at Week 8-1.16 ± 2.06112.49 ± 2.12823.50 ± 2.04225.42 ± 2.07114.96 ± 1.953
Statistical analysis
  • Placebo vs TAK-861 0.5 mg BID · MMRM · p = =0.001 (The analysis used a linear MMRM with fixed effects for Baseline, age, prior use of narcolepsy medications, treatment, visit, and treatment-by-visit interaction as covariates. Reported p-value is adjusted for multiplicity.) · Estimate of ls mean difference: 13.65 · 95% CI 7.74 to 19.57LS in LS Mean Difference denotes least squares.
  • Placebo vs TAK-861 2 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM with fixed effects for Baseline, age, prior use of narcolepsy medications, treatment, visit, and treatment-by-visit interaction as covariates. Reported p-value is adjusted for multiplicity.) · Estimate of ls mean difference: 24.67 · 95% CI 18.87 to 30.46An unstructured variance-covariance structure was used.
  • Placebo vs TAK-861 2 mg and 5 mg · MMRM · p = <0.001 (The analysis used a linear MMRM with fixed effects for Baseline, age, prior use of narcolepsy medications, treatment, visit, and treatment-by-visit interaction as covariates. Reported p-value is adjusted for multiplicity.) · Estimate of ls mean difference: 26.58 · 95% CI 20.81 to 32.35An unstructured variance-covariance structure was used.
  • Placebo vs TAK-861 7 mg QD · MMRM · p = <0.001 (The analysis used a linear MMRM with fixed effects for Baseline, age, prior use of narcolepsy medications, treatment, visit, and treatment-by-visit interaction as covariates. Reported p-value is adjusted for multiplicity.) · Estimate of ls mean difference: 16.13 · 95% CI 10.49 to 21.76An unstructured variance-covariance structure was used.
SecondaryChange From Baseline in Epworth Sleepiness Scale (ESS) Total Score at Week 8

The ESS is a subjective, self-administered, validated scale (scored 0 to 3) to respond to each of the 8 questions of daily life that asks participants how likely they are to fall asleep in those situations. The scores are summed to give an overall score of 0 to 24. Higher scores indicate stronger subjective daytime sleepiness, and scores below 10 are considered to be within the normal range. The MMRM was used for analysis.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · score on a scale
Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score at Week 8
score on a scalePlaceboTAK-861 0.5 mg BIDTAK-861 2 mg BIDTAK-861 2 mg and 5 mgTAK-861 7 mg QD
Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score at Week 8-2.50 ± 1.109-8.92 ± 1.085-13.79 ± 1.115-12.81 ± 1.073-11.29 ± 1.064
Statistical analysis
  • Placebo vs TAK-861 0.5 mg BID · MMRM · p = =0.004 (The analysis used a linear MMRM with fixed effects for Baseline, age, prior use of narcolepsy medications, treatment, visit, and treatment-by-visit interaction as covariates. Reported p-value is adjusted for multiplicity.) · Estimate of ls mean difference: -6.42 · 95% CI -9.53 to -3.32An unstructured variance-covariance structure was used.
  • Placebo vs TAK-861 2 mg BID · MMRM · p = <0.001 (The analysis used a linear MMRM with fixed effects for Baseline, age, prior use of narcolepsy medications, treatment, visit, and treatment-by-visit interaction as covariates. Reported p-value is adjusted for multiplicity.) · Estimate of ls mean difference: -11.3 · 95% CI -14.44 to -8.16An unstructured variance-covariance structure was used.
  • Placebo vs TAK-861 2 mg and 5 mg · MMRM · p = <0.001 (The analysis used a linear MMRM with fixed effects for Baseline, age, prior use of narcolepsy medications, treatment, visit, and treatment-by-visit interaction as covariates. Reported p-value is adjusted for multiplicity.) · Estimate of ls mean difference: -10.31 · 95% CI -13.35 to -7.27An unstructured variance-covariance structure was used.
  • Placebo vs TAK-861 7 mg QD · MMRM · p = <0.001 (The analysis used a linear MMRM with fixed effects for Baseline, age, prior use of narcolepsy medications, treatment, visit, and treatment-by-visit interaction as covariates. Reported p-value is adjusted for multiplicity.) · Estimate of ls mean difference: -8.79 · 95% CI -11.84 to -5.75An unstructured variance-covariance structure was used.
SecondaryWeekly Cataplexy Rate (WCR) at Week 8

Participants completed a daily patient-reported sleep diary to record self-reported narcolepsy symptoms. Participants recorded episodes of cataplexy attacks in the diary. The total number of events averaged for a week were reported. WCR = (total number of cataplexy attacks over a number of non-missing diary days for a given duration/number of non-missing diary days in that duration)\*7. The generalized estimating equations (GEE) model was used for analysis.

Time frame:
Week 8
Reported as:
Least squares mean · cataplexy attacks per week
Weekly Cataplexy Rate (WCR) at Week 8
cataplexy attacks per weekPlaceboTAK-861 0.5 mg BIDTAK-861 2 mg BIDTAK-861 2 mg and 5 mgTAK-861 7 mg QD
Weekly Cataplexy Rate (WCR) at Week 88.76 (5.68 to 13.51)4.24 (2.60 to 6.92)3.14 (1.65 to 5.98)2.48 (1.30 to 4.73)5.89 (3.64 to 9.53)
Statistical analysis
  • Placebo vs TAK-861 0.5 mg BID · GEE · p = =0.250 (GEE model featuring a negative binomial distribution was used for analysis where incidence rate was exponentiated LS mean \& incidence rate ratio (IRR) was exponentiated LS mean difference from placebo. Reported p-value is adjusted for multiplicity.) · Irr: 0.48 · 95% CI 0.25 to 0.93
  • Placebo vs TAK-861 2 mg BID · GEE · p = =0.034 (The GEE model featuring a negative binomial distribution was used for analysis where the incidence rate was the exponentiated LS mean and the IRR was the exponentiated LS mean difference from placebo. Reported p-value is adjusted for multiplicity.) · Irr: 0.36 · 95% CI 0.16 to 0.79
  • Placebo vs TAK-861 2 mg and 5 mg · GEE · p = =0.003 (The GEE model featuring a negative binomial distribution was used for analysis where the incidence rate was the exponentiated LS mean and the IRR was the exponentiated LS mean difference from placebo. Reported p-value is adjusted for multiplicity.) · Irr: 0.28 · 95% CI 0.13 to 0.60
  • Placebo vs TAK-861 7 mg QD · GEE · p = =0.250 (The GEE model featuring a negative binomial distribution was used for analysis where the incidence rate was the exponentiated LS mean and the IRR was the exponentiated LS mean difference from placebo. Reported p-value is adjusted for multiplicity.) · Irr: 0.67 · 95% CI 0.35 to 1.29
SecondaryNumber of Participants With at Least One Treatment-emergent Adverse Event (TEAE)

An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not the occurrence was considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an AE with an onset that occurred after receiving study drug.

Time frame:
From first dose of the study drug up to end of the study (up to 3 months)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE)
ParticipantsPlaceboTAK-861 0.5 mg BIDTAK-861 2 mg BIDTAK-861 2 mg and 5 mgTAK-861 7 mg QD
Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE)713152121

Adverse events

Collected over From first dose of the study drug up to end of the study (up to 3 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/22 (0%)0/22 (0%)5/22 (22.7%)
TAK-861 0.5 mg BID0/23 (0%)0/23 (0%)11/23 (47.8%)
TAK-861 2 mg BID0/21 (0%)0/21 (0%)15/21 (71.4%)
TAK-861 2 mg/5 mg0/23 (0%)1/23 (4.3%)20/23 (87%)
TAK-861 7 mg QD0/23 (0%)0/23 (0%)20/23 (87%)
Most frequent serious events
Most frequent serious events
EventPlaceboTAK-861 0.5 mg BIDTAK-861 2 mg BIDTAK-861 2 mg/5 mgTAK-861 7 mg QD
Ankle fractureInjury, poisoning and procedural complications0/220/230/211/230/23
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPlaceboTAK-861 0.5 mg BIDTAK-861 2 mg BIDTAK-861 2 mg/5 mgTAK-861 7 mg QD
InsomniaPsychiatric disorders1/225/2310/2113/2315/23
Micturition urgencyRenal and urinary disorders1/225/234/2112/239/23
PollakiuriaRenal and urinary disorders1/223/237/217/2312/23
Salivary hypersecretionGastrointestinal disorders1/222/232/216/232/23
HeadacheNervous system disorders1/221/233/212/232/23
Middle insomniaPsychiatric disorders0/221/230/213/230/23
EpistaxisRespiratory, thoracic and mediastinal disorders0/220/232/210/230/23
Increased appetiteMetabolism and nutrition disorders1/220/232/211/231/23
NasopharyngitisInfections and infestations0/220/232/212/232/23
ConstipationGastrointestinal disorders0/220/230/210/232/23

Baseline characteristics

Safety Analysis Set included all participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboTAK-861 0.5 mg BIDTAK-861 2 mg BIDTAK-861 2 mg and 5 mgTAK-861 7 mg QDTotal
Mean37.5 ± 11.8632.7 ± 11.0631.7 ± 11.3134.7 ± 11.4833.3 ± 11.9434 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTAK-861 0.5 mg BIDTAK-861 2 mg BIDTAK-861 2 mg and 5 mgTAK-861 7 mg QDTotal
Female14119141058
Male8121291354
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTAK-861 0.5 mg BIDTAK-861 2 mg BIDTAK-861 2 mg and 5 mgTAK-861 7 mg QDTotal
Hispanic or Latino321028
Not Hispanic or Latino1921202320103
Unknown or Not Reported000011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboTAK-861 0.5 mg BIDTAK-861 2 mg BIDTAK-861 2 mg and 5 mgTAK-861 7 mg QDTotal
American Indian or Alaska Native000000
Asian120328
Native Hawaiian or Other Pacific Islander000000
Black or African American212016
White191919192096
More than one race010102
Unknown or Not Reported000000
Average Sleep Latency From the Maintenance of Wakefulness Test (MWT)
Average Sleep Latency From the Maintenance of Wakefulness Test (MWT)(minutes)PlaceboTAK-861 0.5 mg BIDTAK-861 2 mg BIDTAK-861 2 mg and 5 mgTAK-861 7 mg QDTotal
Mean6.1 ± 8.825.6 ± 7.893.9 ± 5.984.2 ± 3.633.6 ± 4.874.7 ± 6.48
08

Study locations

57 sites
  • Sleep Disorders Center of Alabama
    Birmingham, Alabama 35213-1966, United States
  • Stanford Center for Sleep Sciences and Medicine
    Redwood City, California 94063-3132, United States
  • SDS Clinical Trials, Inc.
    Santa Ana, California 92705-8519, United States
  • Delta Waves LLC - Hunt - PPDS, Sleep Disorder and Research Center
    Colorado Springs, Colorado 80918, United States
  • Florida Pediatric Research Institute
    Orlando, Florida 32803-1468, United States
  • Neurotrials Research
    Atlanta, Georgia 30342-1743, United States
  • Georgia Neuro Center
    Gainesville, Georgia 30501-3883, United States
  • University of Kansas Medical Center Research Institute, Inc.
    Kansas City, Kansas 66160-0001, United States
  • Neurocare Inc
    Newton, Massachusetts 02459-3233, United States
  • Henry Ford Medical Center - Columbus
    Novi, Michigan 48377, United States
  • St. Lukes Sleep Medicine and Research Center
    Chesterfield, Missouri 63017-3406, United States
  • Research Carolina Elite
    Denver, North Carolina 28037, United States
  • ARSM Research, LLC
    Huntersville, North Carolina 28078-5082, United States
  • Intrepid Research
    Cincinnati, Ohio 45227-2172, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195-0001, United States
  • Ohio Sleep Medicine Institute
    Dublin, Ohio 43017-3521, United States
  • Medical University of South Carolina - PPDS
    Charleston, South Carolina 29425-5712, United States
  • Bogan Sleep Consultants, LLC
    Columbia, South Carolina 29201-2923, United States
  • Comprehensive Sleep Medicine Associates - Sugar Land
    Houston, Texas 77030-2042, United States
  • Sleep Therapy and Research Center
    San Antonio, Texas 78229-4849, United States
  • Children's Specialty Group
    Norfolk, Virginia 23510-1021, United States
  • Woolcock Institute of Medical Research, Sleep and Circadian Research Group
    Glebe, New South Wales 2037, Australia
  • Terveystalo Helsinki Sleep Clinic
    Helsinki, Uusimaa 00380, Finland
  • Hopital Pierre-Paul Riquet
    Toulouse, Haute-Garonne 31000, France
  • CHU Gui De Chauliac
    Montpellier, Herault 34090, France
  • CHU de Grenoble
    La Tronche, Isere 38700, France
  • Hopital de la Pitie Salpetriere
    Paris, 75013, France
  • Universitaet Regensburg am Bezirksklinikum
    Regensburg, Bayern 93053, Germany
  • Somni Bene Institut fur Medizinische Forschung und Schlafmedizin Schwerin GmbH
    Schwerin, Mecklenburg-Vorpommern 19053, Germany
  • Charite - Universitatsmedizin Berlin
    Berlin, 10117, Germany
  • Klinische Forschung Hamburg
    Hamburg, 20253, Germany
  • IRCCS Istituto delle Scienze Neurologiche di Bologna, Dipartimento di Scienze Biomediche e Neuromotorie
    Bellaria, Bologna 40139, Italy
  • Fondazione PTV Policlinico Tor Vergata, Centro del Sonno e del Trattamento Neurologico delle Fragilta
    Roma, Lazio 00133, Italy
  • Istituto Neurologico Mediterraneo Neuromed, Centro Per La Diagnosi E la Cura Del Sonno
    Pozzilli, Molise 86077, Italy
  • Akita University Hospital
    Akita-Shi, Akita 010-8543, Japan
  • Kurume University Hospital
    Kurume-Shi, Hukuoka 830-0011, Japan
  • Howakai Kuwamizu Hospital, Chuo-Ku
    Kumamoto-Shi, Kumamoto 862-0954, Japan
  • Gokeikai Osaka Kaisei Hospital, Yodogawa-Ku
    Osaka-Shi, Osaka 532-0003, Japan
  • Koishikawa Tokyo Hospital
    Bunkyo-Ku, Tokyo 112-0012, Japan
  • National Center of Neurology and Psychiatry
    Kodaira-Shi, Tokyo 187-8551, Japan
  • Yoyogi Sleep Disorder Center
    Shibuya-Ku, Tokyo 151-0053, Japan
  • Aichi Medical University Hospital
    Nagakute, 480-1195, Japan
  • RESM respiratory and sleep medical-care clinic, Yokoharna Building, 4Floor
    Yokohama, 222-0033, Japan
  • Kempenhaeghe - PPDS
    Heeze, Noord-Brabant 5591 VE, Netherlands
  • Slaap-Waakcentrum SEIN Heemstede
    Heemstede, Noord-Holland 2103 SW, Netherlands
  • University of Oslo
    Oslo, 0450, Norway
  • Hospital Universitario Araba Santiago, Unidad Funcional de Sueno
    Vitoria, Alava 01004, Spain
  • Hospital General de Castello, Sleep Unit
    Castellón De La Plana, Castellon 12004, Spain
  • Hospital de La Ribera, Unidad de Sueno
    Alzira, Valencia 46600, Spain
  • Hospital Universitario Vall d'Hebron - PPDS
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona, Neurology Service, scale 8-4th floor
    Barcelona, 08036, Spain
  • Instituto de Investigaciones del Sueno
    Madrid, 28036, Spain
  • Hospital Vithas Madrid Arturo Soria
    Madrid, 28046, Spain
  • Sahlgrenska Universitetssjukhuset
    Goteborg, Vastra Gotalands Lan 413 46, Sweden
  • Klinik Barmelweid AG
    Barmelweid, Aargau (de) 5017, Switzerland
  • Neurocenter of Southern Switzerland
    Lugano, Ticino (it) 6900, Switzerland
  • Universitaetsspital Bern, Department of Neurology
    Bern, 3010, Switzerland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Dec 2023, 11 months.

Results were first posted in Jan 2025, 1 year after primary completion.

Of 15 phase 2 interventional studies under Narcolepsy, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2023
First posted
Jan 18, 2023
StartActual
Jan 9, 2023
Primary completionActual
Dec 14, 2023
CompletionActual
Dec 14, 2023
Results first posted
Jan 9, 2025
Last update
Jan 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05687903
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jan 18, 2023
Start date
Jan 9, 2023
Primary completion
Dec 14, 2023
Completion
Dec 14, 2023
Results posted
Jan 9, 2025
Last update
Jan 9, 2025

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oveporexton

Start the discussion